Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Teusink-Cross, Ashley  [Clear All Filters]
2024
Khandelwal P, Langenberg L, Luebbering N, Lake K, Butcher A, Werling K, Ramos KN, Taggart C, Choe HK, Vasu S, et al. A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults. Blood. 2024.
2023
Jodele S, Dandoy CE, Aguayo-Hiraldo P, Lane A, Teusink-Cross A, Sabulski A, Mizuno K, Laskin BL, Freedman JLawrence, Davies SM. Prospective Multi-Institutional Study of Eculizumab to Treat High-Risk Stem Cell Transplant Associated TMA. Blood. 2023.
2022
Mizuno K, Dandoy CE, Teusink-Cross A, Davies SM, Vinks AA, Jodele S. Eculizumab precision dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Blood Adv. 2022.
2021
Hughes K, Garrity L, Nelson AS, Lane A, Teusink-Cross A. Comparison of levetiracetam versus phenytoin/fosphenytoin for busulfan seizure prophylaxis at a pediatric institution. Pediatr Transplant. 2021:e14026.
Edwards A, Teusink-Cross A, Martin LJ, Prows CA, Mehta PA, Ramsey LB. Influence of CYP2D6 metabolizer status on ondansetron efficacy in pediatric patients undergoing hematopoietic stem cell transplantation: A case series. Clin Transl Sci. 2021.
2016
Teusink-Cross A, Davies SM, Danziger-Isakov L, El-Bietar J, Grimley MS. Restrictive palivizumab use does not lead to increased morbidity and mortality in pediatric hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant. 2016.
Jodele S, Dandoy CE, Danziger-Isakov L, Myers KC, El-Bietar J, Nelson A, Wallace G, Teusink-Cross A, Davies SM. Terminal complement blockade after HSCT is safe without meningococcal vaccination. Biol Blood Marrow Transplant. 2016.